Infliximab therapy in Behçet's uveitis Traitement par infliximab dans l'uvéite de Behçet

Alizadegan F., YALÇINBAYIR Ö., UÇAN GÜNDÜZ G., PEHLİVAN Y.

Journal Francais d'Ophtalmologie, cilt.45, sa.9, ss.1036-1041, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 9
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.jfo.2022.04.009
  • Dergi Adı: Journal Francais d'Ophtalmologie
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.1036-1041
  • Anahtar Kelimeler: Anti tumor necrosis factor, Behcet&rsquo, s disease, Infliximab, Noninfectious, Uveitis, NECROSIS-FACTOR-ALPHA, REFRACTORY UVEORETINITIS, FOLLOW-UP, DISEASE, CYTOKINES, INDUCTION, REMISSION
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

© 2022 Elsevier Masson SASPurpose: To evaluate the efficacy of infliximab (IFX) therapy in patients with Behçet's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT). Materials and methods: This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic characteristics, ophthalmological examination findings, control of ocular inflammation with IFX, response to treatment and the rate of clinical remission were analyzed in this study. Results: Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5 ± 25.9 months. The mean frequency of recurrences during the IMT was 1.47 ± 0.78 (attacks/year), decreasing to 0.31 ± 0.40 (attacks/year) with IFX (P < 0.001). Visual acuity improved significantly in the 1st month of IFX treatment (P = 0.026). Partial response to treatment was achieved in 91.4% of cases. Conclusion: IFX is a safe and effective treatment in cases of BU refractory to conventional IMT.